Yahoo Finance

SCD-PROTECT publication: High SCD risk despite modern GDMT across 19,500+ LifeVest® patients

NICM: 6.10 appropriate treatments per 100 patient-years MI/CAD: 8.64 appropriate treatments per 100 patient-years The rate of appropriate LifeVest treatments in SCD-PROTECT was significantly higher ...

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

Strong survival data extending to 90 daysReal-world experience shows results consistent with clinical trial dataFavorable safety profile – no ...
Business Wire

Treatment with Investigational LentiGlobin™ Gene Therapy for Sickle Cell Disease (bb1111) Results in Complete Elimination of SCD-Related Severe Vaso-Occlusive Events in Group ...

LentiGlobin gene therapy for sickle cell disease (bb1111) is an investigational treatment being studied as a potential treatment for SCD. bluebird bio’s clinical development program for LentiGlobin ...

Spherix Global Insights Reveals Persistent High Disease Burden and Heavy Reliance on Pain Management in U.S. Sickle Cell Disease Despite Awareness of Disease-Modifying Therapies

New research from Spherix Global Insights underscores the profound and multifaceted burden faced by patients living with sickle cell disease (SCD), revealing a misalignment between how patients ...
Business Wire

SCD-PROTECT publication: High SCD risk despite modern GDMT across 19,500+ LifeVest ® patients

81.7% of patients were on an SGLT2 inhibitor 74.7% of patients were on an ARNI 95.1% of patients were on a beta-blocker 83.1% of patients were on an MRA Despite high use of GDMT, the rate of ...